Total Payments
$306,621
2024 Payments
$118,278
Companies
37
Transactions
1,043
Medicare Patients
225
Medicare Billing
$338,130
Payment Breakdown by Category
Other$224,805 (73.3%)
Travel$32,883 (10.7%)
Consulting$30,725 (10.0%)
Food & Beverage$17,864 (5.8%)
Education$344.47 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $224,805 | 110 | 73.3% |
| Travel and Lodging | $32,883 | 150 | 10.7% |
| Consulting Fee | $30,725 | 12 | 10.0% |
| Food and Beverage | $17,864 | 762 | 5.8% |
| Education | $344.47 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $85,690 | 121 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $69,055 | 117 | $0 (2024) |
| ITI, Inc. | $58,840 | 116 | $0 (2023) |
| Axsome Therapeutics, Inc. | $26,358 | 36 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25,437 | 36 | $0 (2024) |
| ABBVIE INC. | $23,793 | 74 | $0 (2024) |
| Corium, LLC | $4,650 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,374 | 18 | $0 (2024) |
| Neuronetics, Inc. | $1,174 | 23 | $0 (2020) |
| Lundbeck LLC | $1,010 | 125 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $118,278 | 205 | Janssen Pharmaceuticals, Inc ($53,394) |
| 2023 | $147,307 | 263 | IDORSIA PHARMACEUTICALS US INC ($53,482) |
| 2022 | $28,954 | 96 | ITI, Inc. ($19,694) |
| 2021 | $5,877 | 68 | ITI, Inc. ($5,001) |
| 2020 | $1,041 | 55 | ITI, Inc. ($260.01) |
| 2019 | $2,808 | 189 | Neuronetics, Inc. ($570.55) |
| 2018 | $2,171 | 153 | Neuronetics, Inc. ($424.67) |
| 2017 | $186.64 | 14 | Takeda Pharmaceuticals America, Inc. ($54.36) |
All Payment Transactions
1,043 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/18/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $116.70 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $25.57 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $896.81 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $665.93 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $58.22 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $51.84 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,220.00 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $758.28 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $476.01 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $354.88 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $122.01 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $357.78 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,145.00 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Janssen Scientific Affairs, LLC | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Insomnia | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $253.89 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $113.88 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Insomnia | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | Cash or cash equivalent | $23.43 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | Cash or cash equivalent | $23.43 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | Cash or cash equivalent | $18.98 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Travel and Lodging | In-kind items and services | $18.98 | General |
| Category: Insomnia | ||||||
| 12/02/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 39 | 304 | $584,816 | $232,045 |
| 2022 | 2 | 42 | 107 | $35,862 | $7,357 |
| 2021 | 3 | 74 | 667 | $342,670 | $85,388 |
| 2020 | 2 | 70 | 192 | $26,575 | $13,340 |
Total Patients
225
Total Services
1,270
Medicare Billing
$338,130
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, | Office | 2023 | 13 | 237 | $567,175 | $225,812 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 67 | $17,641 | $6,232 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 77 | $28,280 | $5,976 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 30 | $7,581 | $1,381 | 18.2% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 11 | 498 | $298,800 | $71,607 | 24.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 110 | $31,191 | $10,370 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 59 | $12,679 | $3,411 | 26.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 30 | 103 | $15,450 | $8,476 | 54.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 40 | 89 | $11,125 | $4,864 | 43.7% |
About Jeffrey Richmond
Jeffrey Richmond is a Psychiatry healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2010. The National Provider Identifier (NPI) number assigned to this provider is 1831414507.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jeffrey Richmond has received a total of $306,621 in payments from pharmaceutical and medical device companies, with $118,278 received in 2024. These payments were reported across 1,043 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($224,805).
As a Medicare-enrolled provider, Richmond has provided services to 225 Medicare beneficiaries, totaling 1,270 services with total Medicare billing of $338,130. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Denver, CO
- Active Since 04/06/2010
- Last Updated 05/08/2019
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1831414507
Products in Payments
- SPRAVATO (Drug) $85,881
- CAPLYTA (Drug) $84,277
- QUVIVIQ (Drug) $69,055
- Auvelity (Drug) $26,358
- VRAYLAR (Drug) $23,908
- AZSTARYS (Drug) $3,683
- COBENFY (Drug) $3,410
- NEUROSTAR TMS THERAPY (Device) $1,174
- Azstarys (Drug) $967.40
- REXULTI (Drug) $699.62
- LATUDA (Drug) $663.20
- AUSTEDO (Drug) $604.33
- Trintellix (Drug) $483.34
- TRINTELLIX (Drug) $470.25
- BRINTELLIX (Drug) $440.17
- Qelbree (Drug) $385.81
- NUEDEXTA (Drug) $306.45
- ARISTADA (Drug) $269.47
- Fanapt (Drug) $253.02
- Austedo XR (Drug) $242.12
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Denver
Brenda Czaban, Md, MD
Psychiatry — Payments: $24,850
Psychiatry $24,850
Dr. Joan Shapiro, M.d, M.D
Psychiatry — Payments: $18,928
Psychiatry $18,928
Robert Clark, M.d, M.D
Psychiatry — Payments: $14,022
Psychiatry $14,022
Dr. Sara Markey, M.d, M.D
Psychiatry — Payments: $10,874
Psychiatry $10,874
Stephen Popkin, M.d, M.D
Psychiatry — Payments: $9,254
Psychiatry $9,254
Daniela Stamatoiu, M.d, M.D
Psychiatry — Payments: $6,827
Psychiatry $6,827